 The Food and Drug Administration placed a cancer study from Beam Therapeutics on hold Monday, leading Beam stock to topple. The post FDA Slaps CRISPR Cousin With A Hold; Beam Therapeutics Stock Collapses appeared first on Investors Business Daily. 